v3.24.3
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations
 9 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations
The following tables represent revenues by geographic region and reportable segment for the three and nine months ended September 30, 2024 and 2023:
Three Months Ended September 30, 2024
(in millions)Technology & Analytics SolutionsResearch & Development SolutionsContract Sales & Medical SolutionsTotal
Revenues:
Americas$797 $969 $72 $1,838 
Europe and Africa626 607 54 1,287 
Asia-Pacific131 586 54 771 
Total revenues$1,554 $2,162 $180 $3,896 
Three Months Ended September 30, 2023
(in millions)Technology & Analytics SolutionsResearch & Development SolutionsContract Sales & Medical SolutionsTotal
Revenues:
Americas$761 $1,017 $78 $1,856 
Europe and Africa519 520 50 1,089 
Asia-Pacific151 585 55 791 
Total revenues$1,431 $2,122 $183 $3,736 
Nine Months Ended September 30, 2024
(in millions)Technology & Analytics SolutionsResearch & Development SolutionsContract Sales & Medical SolutionsTotal
Revenues:
Americas$2,323 $2,969 $211 $5,503 
Europe and Africa1,757 1,699 166 3,622 
Asia-Pacific422 1,736 164 2,322 
Total revenues$4,502 $6,404 $541 $11,447 
Nine Months Ended September 30, 2023
(in millions)Technology & Analytics SolutionsResearch & Development SolutionsContract Sales & Medical SolutionsTotal
Revenues:
Americas$2,268 $2,982 $228 $5,478 
Europe and Africa1,606 1,547 146 3,299 
Asia-Pacific457 1,715 167 2,339 
Total revenues$4,331 $6,244 $541 $11,116 
No individual customer represented 10% or more of consolidated revenues for the three and nine months ended September 30, 2024 or 2023.
Transaction Price Allocated to the Remaining Performance Obligations
As of September 30, 2024, approximately $33.3 billion of revenues are expected to be recognized in the future from remaining performance obligations. The Company expects to recognize revenues on approximately 30% of these remaining performance obligations over the next twelve months, on approximately 85% over the next five years, with the balance recognized thereafter. Most of the Company's remaining performance obligations where revenues are expected to be recognized beyond the next twelve months are for service contracts for clinical research in the Company's Research & Development Solutions segment. The customer contract transaction price allocated to the remaining performance obligations differs from backlog in that it does not include wholly unperformed contracts under which the customer has a unilateral right to cancel the arrangement